|
gptkbp:instanceOf
|
antiviral drug
nucleotide reverse transcriptase inhibitor
|
|
gptkbp:administeredBy
|
oral tablet
oral powder
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2001
|
|
gptkbp:ATCCode
|
J05AF07
|
|
gptkbp:available_as_generic
|
yes
|
|
gptkbp:bioavailability
|
25%
|
|
gptkbp:CASNumber
|
202138-50-9
|
|
gptkbp:chemicalClass
|
acyclic nucleoside phosphonate
|
|
gptkbp:combines
|
gptkb:efavirenz
gptkb:lamivudine
emtricitabine
|
|
gptkbp:contraindication
|
severe renal impairment
|
|
gptkbp:developedBy
|
gptkb:Gilead_Sciences
|
|
gptkbp:drugClass
|
antiretroviral therapy
nucleotide analogue
|
|
gptkbp:eliminationHalfLife
|
17 hours
|
|
gptkbp:excretion
|
kidneys
|
|
gptkbp:has_full_name
|
gptkb:tenofovir_disoproxil_fumarate
|
|
gptkbp:hasMolecularFormula
|
C19H30N5O10P·C4H4O4
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
tenofovir DF
|
|
gptkbp:includes
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
|
gptkbp:interactsWith
|
gptkb:didanosine
gptkb:lopinavir/ritonavir
gptkb:atazanavir
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Viread
|
|
gptkbp:mechanismOfAction
|
inhibits HIV reverse transcriptase
inhibits HBV polymerase
|
|
gptkbp:metabolism
|
tenofovir
|
|
gptkbp:patentExpired
|
2017 (US)
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:prodrugOf
|
tenofovir
|
|
gptkbp:risk_in_pregnancy
|
low
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
headache
decreased bone mineral density
renal toxicity
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:used_for_pre-exposure_prophylaxis
|
yes
|
|
gptkbp:usedFor
|
HIV infection
chronic hepatitis B
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:tenofovir_disoproxil_fumarate
|
|
gptkbp:bfsLayer
|
6
|